Last reviewed · How we verify

NCT03831646

Clinical, Psychological and Genetic Characteristics in Dermatological Patients

Completed Last updated 20 August 2019
What this trial tests

trial in Atopic Dermatitis in 150 participants. Completed in 30 July 2019.

Timeline
20 January 2019
Primary endpoint
10 July 2019
30 July 2019

Quick facts

Lead sponsorAstana Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date20 January 2019
Primary completion10 July 2019
Estimated completion30 July 2019
Sites1 location across Kazakhstan

Conditions studied

Sponsor

Astana Medical University

Who can join

18 and older, any sex, with Atopic Dermatitis or Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atopic dermatitis (AD) and psoriasis (PS) are chronic, relapsing dermatological disorders with a high rate of psychiatric co-morbid pathology represented with depression. Brain Derived Neurotrophic Factor (BDNF) belongs to the neurotrophin family and widely studied in pathophysiology of psychiatric and dermatological disorders. A biological stress response system by altered hypothalamic-pituitary-adrenal (HPA) axis as well hypothalamic-pituitary-gonadal (HPG) axis may contribute to dermatoses and psychiatric disorders development. Various factors including gender, genetic, psychological stress, socioeconomic factors also affect the course of dermatoses. A 10-week, case-control study evaluate clinical, psychological and biochemical parameters in AD and PS patients, and healthy control volunteers (HC) depending on gender and BDNF rs6265 gene polymorphism. All parameters are evaluated twice: at disease exacerbation (study baseline) and week 10. The following methods are conducted: assessment of dermatological status, using Scoring of Atopic Dermatitis (SCORAD) and Psoriasis Area and Severity Index (PASI); assessment of depression and anxiety according to DSM-V criteria and with Hamilton Depression Rating Scale (HAM-D) and with Hamilton Anxiety Rating Scale (HAM-A); analysis of serum BDNF (ng/ml), cortisol (nmol/L), testosterone (ng/dL) and IgE levels (IU/ml, AD only); DNA extraction and genotyping of BDNF variants.The study will last during 4-5 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

Other Astana Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03831646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing